Skip to main content

Table 4 Relative survival proportions

From: Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981-2014

 

1981-85

1986-90

1991-95

1996-2000

2001-05

2006-10

2011-14a

β RS (SE)

p-value

 

Men

0.67

(0.64,0.70)

0.71

(0.68,0.74)

0.73

(0.70,0.76)

0.72

(0.70,0.75)

0.75

(0.72,0.77)

0.77

(0.75,0.79)

0.77

(0.75,0.79)

0.004 (0.001)

1.3E-06b

 

Women

0.63

(0.59,0.67)

0.68

(0.64,0.72)

0.65

(0.61,0.69)

0.70

(0.67,0.74)

0.70

(0.67,0.73)

0.72

(0.69,0.75)

0.74

(0.71,0.77)

0.003 (0.001)

4.5E-06b

Men

Age (years)

 

0–49

0.90

(0.84,0.95)

0.85

(0.78,0.90)

0.93

(0.88,0.97)

0.92

(0.86,0.95)

0.89

(0.83,0.93)

0.91

(0.85,0.95)

0.94

(0.84,0.98)

0.001 (0.001)

0.623

 

50–64

0.78

(0.74,0.81)

0.81

(0.78,0.85)

0.83

(0.80,0.86)

0.84

(0.80,0.87)

0.84

(0.81,0.86)

0.83

(0.81,0.86)

0.89

(0.85,0.91)

0.003 (0.001)

0.006b

 

65–79

0.69

(0.65,0.72)

0.68

(0.65,0.72)

0.72

(0.70,0.75)

0.73

(0.70,0.76)

0.75

(0.72,0.78)

0.78

(0.76,0.81)

0.78

(0.73,0.81)

0.005 (0.001)

7.6E-07b

 

80+

0.53

(0.45,0.63)

0.65

(0.57,0.73)

0.63

(0.56,0.71)

0.60

(0.53,0.66)

0.64

(0.58,0.70)

0.68

(0.62,0.73)

0.63

(0.54,0.72)

0.007 (0.003)

0.015b

 

Morphology

 

Non-inv pap carcinoma LG

0.85

(0.79,0.89)

0.92

(0.87,0.95)

0.91

(0.87,0.95)

0.93

(0.88,0.96)

0.91

(0.87,0.94)

0.94

(0.90,0.97)

0.93

(0.84,0.97)

0.003 (0.001)

0.001b

 

Non-inv pap carcinoma HG

0.94

(0.18,1.00)

0.76

(0.63,0.85)

0.84

(0.71,0.92)

0.80

(0.66,0.88)

0.82

(0.72,0.88)

0.87

(0.80,0.92)

0.88

(0.77,0.94)

0.004 (0.002)

0.050

 

Dysplasia

0.76

(0.56,0.87)

0.63

(0.47,0.76)

0.76

(0.61,0.86)

0.83

(0.68,0.92)

0.85

(0.67,0.93)

0.83

(0.66,0.92)

0.74

(0.54,0.86)

0.004 (0.003)

0.155

 

Carcinoma in situ

0.79

(0.45,0.93)

0.62

(0.48,0.74)

0.64

(0.51,0.75)

0.64

(0.53,0.73)

0.84

(0.69,0.92)

0.83

(0.71,0.90)

0.91

(0.70,0.97)

0.013 (0.004)

1.6E-04b

 

Inv carcinoma

0.47

(0.43,0.51)

0.49

(0.45,0.52)

0.51

(0.48,0.55)

0.50

(0.47,0.54)

0.54

(0.50,0.57)

0.55

(0.52,0.58)

0.58

(0.54,0.63)

0.003 (0.001)

2.3E-04b

 

Stage

 

Localised

0.73

(0.69,0.76)

0.76

(0.73,0.79)

0.77

(0.74,0.79)

0.77

(0.74,0.79)

0.80

(0.78,0.82)

0.82

(0.80,0.84)

0.81

(0.77,0.84)

0.004 (0.001)

7.0E-06b

 

Regional advanced

0.25

(0.17,0.34)

0.27

(0.20,0.36)

0.28

(0.19,0.38)

0.23

(0.15,0.31)

0.25

(0.18,0.32)

0.27

(0.21,0.33)

0.22

(0.04,0.49)

<0.001 (0.002)

0.991

 

Distant advanced

0.05

(0.02,0.11)

0.08

(0.04,0.14)

0.05

(0.01,0.15)

0.04

(0.01,0.12)

0.09

(0.04,0.17)

0.07

(0.03,0.12)

0.05

(0.01,0.030)

−0.001 (0.002)

0.509

Women

Age (years)

 

0–49

0.90

(0.76,0.96)

0.82

(0.68,0.90)

0.87

(0.75,0.94)

0.95

(0.84,0.99)

0.82

(0.67,0.91)

0.79

(0.65,0.88)

0.78

(0.61,0.89)

−0.003 (0.003)

0.409

 

50–64

0.78

(0.71,0.84)

0.85

(0.78,0.90)

0.79

(0.72,0.84)

0.84

(0.78,0.89)

0.82

(0.76,0.86)

0.89

(0.84,0.92)

0.86

(0.77,0.92)

0.004 (0.002)

0.032b

 

65–79

0.61

(0.56,0.66)

0.64

(0.59,0.69)

0.65

(0.60,0.69)

0.72

(0.67,0.76)

0.74

(0.69,0.79)

0.72

(0.67,0.76)

0.70

(0.63,0.77)

0.008 (0.001)

1.5E-05b

 

80+

0.51

(0.40,0.62)

0.59

(0.48,0.70)

0.52

(0.42,0.61)

0.53

(0.44,0.62)

0.51

(0.44,0.59)

0.59

(0.51,0.66)

0.68

(0.56,0.79)

0.004 (0.003)

0.195

 

Morphology

 

Non-inv pap carcinoma LG

0.92

(0.82,0.96)

0.94

(0.83,0.98)

0.90

(0.82,0.94)

0.92

(0.85,0.96)

0.90

(0.84,0.94)

0.91

(0.85,0.95)

0.89

(0.78,0.95)

−0.001 (0.001)

0.585

 

Non-inv pap carcinoma HG

0.74

(0.36,0.92)

0.90

(0.34,0.99)

0.71

(0.51,0.83)

0.88

(0.27,0.99)

0.79

(0.60,0.90)

0.81

(0.68,0.89)

0.88

((0.69,0.95)

<0.001 (0.005)

0.986

 

Dysplasia

0.52

(0.35,0.66)

0.65

(0.46,0.79)

0.84

(0.46,0.96)

0.78

(0.54,0.91)

0.96

(0.11,1.00)

0.78

(0.57,0.90)

0.93

(0.46,0.99)

0.011 (0.005)

0.035b

 

Carcinoma in situ

0.39

(0.15,0.62)

0.60

(0.41,0.75)

0.73

(0.52,0.86)

0.81

(0.57,0.93)

0.62

(0.50,0.72)

0.71

(0.51,0.84)

0.83

(0.29,0.97)

0.010 (0.006)

0.082

 

Inv carcinoma

0.43

(0.38,0.48)

0.43

(0.37,0.48)

0.42

(0.37,0.47)

0.46

(0.41,0.51)

0.45

(0.40,0.50)

0.51

(0.46,0.56)

0.50

(0.43,0.57)

0.003 (0.001)

0.010b

 

Stage

 

Localised

0.70

(0.66,0.74)

0.74

(0.69,0.78)

0.70

(0.66,0.73)

0.76

(0.72,0.79)

0.77

(0.74,0.80)

0.79

(0.76,0.82)

0.79

(0.74,0.83)

0.004 (0.001)

9.2E-06b

 

Regional advanced

0.14

(0.06,0.24)

0.19

(0.10,0.29)

0.18

(0.10,0.28)

0.30

(0.20,0.40)

0.18

(0.11,0.26)

0.25

(0.16,0.35)

0.30

(0.18,0.43)

0.004 (0.02)

0.055

 

Distant advanced

0.04

(0.01,0.15)

0.09

(0.01,0.27)

0.02

(0.01,0.10)

0.04

(0.01,0.10)

0.06

(0.01,0.16)

0.11

(0.05,0.22)

0.08

(0.01,0.41)

−0.010 (0.006)

0.136

  1. 5-year relative survival proportions (Ederer II) including confidence intervals by sex, morphology group and stage stratified by 5-year diagnosis intervals from 1981 to 2014. We applied internal age-standardization based on the latest diagnostic period 2011-14. Average annual relative survival proportion changes \( \left({\widehat{\beta}}_{RS}\right) \) are reported together with standard error (SE) and p-value for the test of a significant survival trend.
  2. aThe relative survival values for the latest diagnostic period are based on a period approach
  3. Significant p-values (based on the 5 % threshold) are marked withb
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us